NCT03958721View on ClinicalTrials.gov

Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

October 26, 2023

Study Completion Date

October 26, 2023

Conditions
Resistant Breast CancerNon-metastatic Invasive Breast Cancer
Interventions
DRUG

Capecitabine

1,000 mg/m2 twice daily taken by mouth every other week

RADIATION

Radiotherapy

Once daily (Monday through Friday) for six weeks

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
lead

A Bapsi Chakravarthy, MD

OTHER

NCT03958721 - Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer | Biotech Hunter | Biotech Hunter